AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Today's episode features three experts, Josh Hardman, Michael Haichin, and Graham Pechenik as they analyze atai’s S-1 in advance of their IPO.
In this episode, we discuss:
- How atai went from idea to IPO in 3 years
- An overview of atai’s drug development programs and enabling technologies
- The platform’s strategy and risks
Links to topics in this episode:
Atai life sciences
Etifoxine
Esketamine & arketamine
Atai’s S-1
Psychedelic Pharmacist Association
Calyx Law
Psilocybin Alpha, Noetic Fund
kratom, Salvinorin A, BNC210, mitragynine
Mike Novogratz, Christian Angermayer, George Goldsmith, Ekaterina Malievskaia, Peter Thiel
PureTech Health, Akili Interactive Labs
BT’s DemeRx Episode
Viridia Life Sciences, EmpathBio, Kures, Recognify Life Sciences
Read the transcript here.
Watch episode 9 on YouTube.
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh
Find us at businesstrip.fm
Follow us on Instagram and Twitter!
Theme musi
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode